Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) Price Target at $5.25

Key Points

• Context Therapeutics Inc. has received an average consensus recommendation of "Buy" from six analysts, with five giving a buy rating and one a strong buy rating.
• The average 12-month price target for Context Therapeutics is $5.25, though recent target prices from analysts vary from $4.00 to $9.00.
• In the most recent quarter, Context Therapeutics reported earnings per share of ($0.09), missing analysts' expectations of ($0.06).

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been given a consensus rating of "Buy" by the six brokerages that are presently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $5.25.

CNTX has been the subject of a number of recent analyst reports. Piper Sandler reissued an "overweight" rating and issued a $4.00 price objective (down previously from $4.50) on shares of Context Therapeutics in a research report on Thursday, June 26th. HC Wainwright reduced their target price on Context Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Finally, D. Boral Capital restated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, August 7th.

Context Therapeutics Stock Down 0.1%

Shares of Context Therapeutics stock traded down $0.00 during trading on Tuesday, reaching $0.84. The company's stock had a trading volume of 42,938 shares, compared to its average volume of 142,436. The company has a market cap of $74.90 million, a price-to-earnings ratio of -2.32 and a beta of 1.90. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.59. The company has a 50-day simple moving average of $0.79 and a two-hundred day simple moving average of $0.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). As a group, analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current year.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in Context Therapeutics in the 4th quarter worth $29,000. Citadel Advisors LLC purchased a new position in Context Therapeutics in the 4th quarter worth $31,000. Shay Capital LLC purchased a new position in Context Therapeutics in the 4th quarter worth $52,000. Millennium Management LLC raised its stake in Context Therapeutics by 24.2% in the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company's stock worth $188,000 after acquiring an additional 34,835 shares during the last quarter. Finally, MPM Bioimpact LLC purchased a new position in Context Therapeutics in the 4th quarter worth $15,441,000. Hedge funds and other institutional investors own 14.03% of the company's stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.